1,244 reports of this reaction
2.8% of all AFLIBERCEPT reports
#6 most reported adverse reaction
VISUAL ACUITY REDUCED is the #6 most commonly reported adverse reaction for AFLIBERCEPT, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,244 FDA adverse event reports linking AFLIBERCEPT to VISUAL ACUITY REDUCED. This represents approximately 2.8% of all 43,844 adverse event reports for this drug.
Patients taking AFLIBERCEPT who experience visual acuity reduced should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL ACUITY REDUCED is a less commonly reported adverse event for AFLIBERCEPT, but still significant enough to appear in the safety profile.
In addition to visual acuity reduced, the following adverse reactions have been reported for AFLIBERCEPT:
The following drugs have also been linked to visual acuity reduced in FDA adverse event reports:
VISUAL ACUITY REDUCED has been reported as an adverse event in 1,244 FDA reports for AFLIBERCEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL ACUITY REDUCED accounts for approximately 2.8% of all adverse event reports for AFLIBERCEPT, making it a notable side effect.
If you experience visual acuity reduced while taking AFLIBERCEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.